ORYZON Presents Efficacy and Safety Results of its CLEPSIDRA Trial with Iadademstat in ED-SCLC Patients at ESMO-2020

MADRID, Spain and CAMBRIDGE, Mass., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announces today pre-final data from CLEPSIDRA, a Phase II trial investigating iadademstat in combination with standard of-care in rel